ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Lees Pharmaceutical Holdings Ltd (PK)

Lees Pharmaceutical Holdings Ltd (PK) (LPCUF)

0,1903
0,00
(0,00%)
Geschlossen 13 Juli 10:00PM

Lees Pharmaceutical Holdings Ltd (PK) (LPCUF) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
0,1903
( - )
Gebot
0,0001
Fragen
345.200,20
Volumen
-
Durchschnittliches Volumen (3 Mio.)
US$ 773.322
Finanzvolumen
-
0,00 Tagesbereich 0,00
0,1882 52-Wochen-Bereich 0,1903
Marktkapitalisierung
Unternehmenswert
438,962M
Handelsende
0,1903
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
VWAP
-
Erlöse (LTM)
1,44B
Nettogewinn (LTM)
91,94M
Ausgegebene Aktien
588.835.343
Streubesitz (%)
42,06%
Institutioneller Besitz (%)
12,05%
Dividendenrendite (LTM)
0,05 (4,13%)
Kurs-Gewinn-Verhältnis
6,79
Kurs-Umsatz-Verhältnis (KUV)
0,43
Gewinn pro Aktie (EPS)
0,16
Beta
0,57

Über Lees Pharmaceutical Holdings Ltd (PK)

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman’s health, pediatrics, rare di... Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman’s health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Socazolimab Injection for Recurrent or metastatic cervical cancer; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat urea cycle disorders; Apremilast Tablets for Plaque psoriasis; and Azilsartan Tablets for hypertension. The Licensed-In Products segment offers Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; and Ferplex to treat iron deficiency anemia. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin’s disease; Lutrate for Prostate cancer; Nitric Oxide for Inhalation for Hypoxic respiratory failure associated with pulmonary hypertension; Omacor to treat Omega-3-acid ethyl esters; Zanidip for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong. Mehr anzeigen

Sektor
-
Branche
-
Hauptsitz
Sha Tin, Hong Kong
Gegründet
1994
Lees Pharmaceutical Holdings Ltd (PK) is listed in the sector of the OTC Markets with ticker LPCUF. The last closing price for Lees Pharmaceutical (PK) was US$0,19. Over the last year, Lees Pharmaceutical (PK) shares have traded in a share price range of US$ 0,1882 to US$ 0,1903.

Lees Pharmaceutical (PK) currently has 588.835.343 shares in issue. The market capitalisation of Lees Pharmaceutical (PK) is US$112,06 million. Lees Pharmaceutical (PK) has a price to earnings ratio (PE ratio) of 6.79.

LPCUF Neueste Nachrichten

Keine Nachrichten vorhanden.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
12000.19030.19030.190300CS
26000.19030.19030.190300CS
520.00211.115834218920.18820.19030.1882190.1903CS
156-0.0097-4.850.20.20.1882260.18928182CS
260-1.3541-87.67806267811.54441.54440.00015530.28971906CS

LPCUF - Frequently Asked Questions (FAQ)

What is the current Lees Pharmaceutical Holdings Ltd (PK) share price?
The current share price of Lees Pharmaceutical Holdings Ltd (PK) is US$ 0,1903
How many Lees Pharmaceutical Holdings Ltd (PK) shares are in issue?
Lees Pharmaceutical Holdings Ltd (PK) has 588.835.343 shares in issue
What is the market cap of Lees Pharmaceutical Holdings Ltd (PK)?
The market capitalisation of Lees Pharmaceutical Holdings Ltd (PK) is USD 112,06M
What is the 1 year trading range for Lees Pharmaceutical Holdings Ltd (PK) share price?
Lees Pharmaceutical Holdings Ltd (PK) has traded in the range of US$ 0,1882 to US$ 0,1903 during the past year
What is the PE ratio of Lees Pharmaceutical Holdings Ltd (PK)?
The price to earnings ratio of Lees Pharmaceutical Holdings Ltd (PK) is 6,79
What is the cash to sales ratio of Lees Pharmaceutical Holdings Ltd (PK)?
The cash to sales ratio of Lees Pharmaceutical Holdings Ltd (PK) is 0,43
What is the registered address of Lees Pharmaceutical Holdings Ltd (PK)?
The registered address for Lees Pharmaceutical Holdings Ltd (PK) is Building 20E, Sha Tin, New Territories
What is the Lees Pharmaceutical Holdings Ltd (PK) website address?
The website address for Lees Pharmaceutical Holdings Ltd (PK) is www.leespharm.com

LPCUF Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen